179 related articles for article (PubMed ID: 12853342)
1. Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer.
Piccart M; Parker LM; Pritchard KI
Ann Oncol; 2003 Jul; 14(7):1017-25. PubMed ID: 12853342
[TBL] [Abstract][Full Text] [Related]
2. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Vergote I; Robertson JF; Kleeberg U; Burton G; Osborne CK; Mauriac L; ;
Breast Cancer Res Treat; 2003 May; 79(2):207-11. PubMed ID: 12825855
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
4. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Vergote I; Abram P
Ann Oncol; 2006 Feb; 17(2):200-4. PubMed ID: 16251200
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Bundred N
Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
[TBL] [Abstract][Full Text] [Related]
6. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
Franco S; Perez A; Tan-Chiu E; Frankel C; Vogel CL
Breast Cancer Res Treat; 2004 Nov; 88(2):103-8. PubMed ID: 15564793
[TBL] [Abstract][Full Text] [Related]
7. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Dodwell D; Vergote I
Cancer Treat Rev; 2005 Jun; 31(4):274-82. PubMed ID: 15908126
[TBL] [Abstract][Full Text] [Related]
8. Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Robertson JF; Come SE; Jones SE; Beex L; Kaufmann M; Makris A; Nortier JW; Possinger K; Rutqvist LE
Eur J Cancer; 2005 Feb; 41(3):346-56. PubMed ID: 15691633
[TBL] [Abstract][Full Text] [Related]
9. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
Cheung KL; Owers R; Robertson JF
Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
[TBL] [Abstract][Full Text] [Related]
10. Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.
Morris C; Wakeling A
Endocr Relat Cancer; 2002 Dec; 9(4):267-76. PubMed ID: 12542403
[TBL] [Abstract][Full Text] [Related]
11. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.
Buzdar AU
Drugs Today (Barc); 2004 Sep; 40(9):751-64. PubMed ID: 15538548
[TBL] [Abstract][Full Text] [Related]
12. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
13. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
14. The future of fulvestrant ("Faslodex").
Howell A
Cancer Treat Rev; 2005; 31 Suppl 2():S26-33. PubMed ID: 16198056
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant: expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer.
Chia S; Gradishar W
Breast; 2008 Apr; 17 Suppl 3():S16-21. PubMed ID: 18353647
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
Robertson JF; Howell A; Gorbunova VA; Watanabe T; Pienkowski T; Lichinitser MR
Breast Cancer Res Treat; 2005 Jul; 92(2):169-74. PubMed ID: 15986127
[TBL] [Abstract][Full Text] [Related]
17. Pure oestrogen antagonists for the treatment of advanced breast cancer.
Howell A
Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
[TBL] [Abstract][Full Text] [Related]
18. Clinical development of fulvestrant ("Faslodex").
Howell A; Abram P
Cancer Treat Rev; 2005; 31 Suppl 2():S3-9. PubMed ID: 16198055
[TBL] [Abstract][Full Text] [Related]
19. Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
Buzdar AU
Drugs Today (Barc); 2008 Sep; 44(9):679-92. PubMed ID: 19137123
[TBL] [Abstract][Full Text] [Related]
20. Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Tobias JS
Int J Biochem Cell Biol; 2004 Nov; 36(11):2112-9. PubMed ID: 15313457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
